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Reduced parathyroid functional mass after successful kidney abnormalities responsible for HPT II through the first
transplantation. months [1, 2]. Normalization of renal function corrects
Background. Chronic uremia is responsible for secondary phosphorus retention and increases renal production of
hyperparathyroidism (HPT II). Parathyroid secretion usually calcitriol [2]. Nevertheless, these early favorable eventstends to normalize after kidney transplantation (KT), but the
are not followed by the rapid normalization of parathor-parameters of the reversibility of HPT II remain poorly defined,
mone (PTH) secretion. Detailed studies of the earlyparticularly the intrinsic mechanisms underlying the improve-
ment of parathyroid function. changes after KT show a progressive decrease of the
Methods. The kinetic functional parameters of the ionized mean basal PTH levels, but without complete normaliza-
calcium (iCa)/parathormone (PTH) relationship curve were tion [1, 2]. Biochemical HPT II can persist for several
studied in 11 patients with mild to moderate HPT II one and six years after successful KT [1, 3, 4], even when the glomer-months after successful KT. Hypercalcemia and hypocalcemia
ular filtration rate (GFR) is almost normal [4, 5]. Afterwere induced, respectively, by CaCl2 and Na2-ethylenediamine-
more than one year, many patients still have absolutetetraacetic acid (Na2-EDTA) infusions.
Results. The mean glomerular filtration rate remained stable or relative HPT II with inappropriate PTH levels [6].
during follow-up. Basal PTH decreased from 195 6 54 pg/ml However, the extent of parathyroid function recovery
before KT to 70 6 12 pg/ml six months later (P , 0.005). During and the intrinsic mechanisms underlying the lowering of
the tests, mean PTH levels decreased significantly between the PTH secretion after KT remain incompletely defined. Ittwo measured times for all iCa levels, indicating an improved
has been established that post-KT HPT II is not a reflec-parathyroid function. An analysis of the kinetic parameters of
tion of autonomous function, as the parathyroid glandsthe curves showed significant decreases of the mean maximal
remain sensitive to acute changes in ionized calciumand minimal PTH levels, respectively, from 340 6 91 to 220 6
30 pg/ml (P 5 0.03) and from 25 6 6 to 15 6 5 pg/ml (P 5 0.005). (iCa) and particularly to the suppressive effect of in-
On the other hand, no change was noted in the parathyroid-cell duced hypercalcemia [7, 8]. Furthermore, it has been
calcium-sensitivity parameters (slope, set point) assessed using shown that parathyroid function in renal transplant re-
two different approaches, either the entire curve or the limited
cipients is characterized by a sigmoidal relationshipcalcium-mediated suppression curve.
curve between iCa and PTH [7], as in normal subjectsConclusion. Improvement of the parathyroid function be-
[9]. But information is scarce about the natural coursetween the first and sixth months post-KT seems mainly attribut-
able to a reduction of the parathyroid functional mass. of kidney recipients’ parathyroid function, and it has not
been determined whether the lowered PTH secretion is
due to a reduced parathyroid functional mass or a change
in the regulation of the PTH release by the parathyroidMetabolic abnormalities induced by long-standing re-
cell. This prospective study was undertaken to investi-nal failure lead to renal osteodystrophy for which second-
gate changes in the PTH secretion parameters of theary hyperparathyroidism (HPT II) is one of the major
iCa/PTH relationship curve during the first six monthsfeatures. Successful kidney transplantation (KT) corrects
post-KT in order to define the conditions underlying thethe endocrine and metabolic imbalances and the main
reversibility of HPT II in an homogeneous group of
patients with mild or moderate biochemical HPT II.
Key words: secondary hyperparathyroidism, parathyroid mass, calcium
sensitivity, PTH secretion, parathyroid function, renal graft.
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Table 1. Characteristics of the patients (N 5 11) assay (3H RRA Kit; Incstar, Stillwater, MN, USA) after
before transplantation
extraction through C18OH cartridges. The GFR was eval-
Sex (M/F) 8/3 uated at the same time as the dynamic parathyroid func-
Age yearsa 44.362.3 (27–51) tion tests, one and six months after KT, by means ofNephropathy N
an isotopic method based on the urinary clearance ofInterstitial 2
Glomerular 7 51CrEDTA [10].
Polycystic 2
Dialysis Evaluation of parathyroid functionMode (HD/CAPD) 9/2
Duration months 26619 (1–60) For every patient, parathyroid function was evaluated
Basal PTH pg /mla 195654 (41–665) one- and six-months post-KT. We used the previouslyIonized Ca mmol /liter a 1.2160.02 (1.13–1.25)
described protocol [11] of a PTH secretion-stimulationAlpha-calcidiol therapy N 2
Phosphate binders therapy (CaCO3) N 10 test during which hypocalcemia is progressively induced,
a Data are: mean 6 sem (range) followed two days later by a PTH secretion-suppressibil-
ity test, which consists of progressively inducing hyper-
calcemia.
Parathormone secretion-stimulation test. A total amount
donors. All patients gave their informed consent to par- of 50 mg/kg of body weight of disodium ethylenedi-
ticipate in the study. Characteristics of the patients be- aminetetraacetate (Na2-EDTA; Pharmy II, St-Germain-
fore KT are summarized in Table 1. Three patients had en-Laye, France) was infused intravenously over a three-
a basal PTH of less than 100 pg/ml. Seven had levels hour period. During that time, 500 ml of 5% glucose
between 100 and 500 pg/ml, and one patient had a basal were infused via the same catheter to dilute Na2-EDTA.
PTH level of 665 pg/ml. None of them had hyperphos- Blood samples were withdrawn from the contralateral
phoremia of more than 2.2 mmol/liter. arm at 0, 30, 60, 90, 120, 150, and 180 minutes for simulta-
Exclusion criteria were previous parathyroid surgery, neous measurements of iCa and PTH.
previous KT, or serum creatinine levels above 180 mmol/ Parathormone secretion-suppressibility test. Calcium
liter during the six months of follow-up. After trans- chloride (CaCl2, 100 mg/ml; Brown Medical SA, Bou-
plantation, none of them received phosphate binders or logne, France) was infused intravenously over a three-
vitamin D analogues. The triple-drug immunosuppres- hour period at a constant rate of 3 mg of elemental
sive regimen consisted of corticosteroid, azathioprine, calcium/kg body wt/hr. During that time, 300 ml of 5%
and cyclosporine A. The dose of cyclosporine was ad- glucose were infused via the same catheter to dilute
justed to obtain a residual blood concentration between calcium. Blood samples were withdrawn from the contra-
100 and 200 ng/ml. Methylprednisolone was given intra- lateral arm at 0, 10, 20, 30, 60, 120, and 180 minutes for
venously during the first week at the dose of 120 mg/ simultaneous measurements of iCa and PTH.
day and was then replaced by oral prednisone and pro- From these data, the individual iCa/PTH curves plot-
gressively reduced over three months until a minimal ted for each patient enable the calculation of the usual
dose of 4 mg/day was reached. The mean prednisone secretory parameters of parathyroid function according
dose was 25.8 6 2.7 mg/day at one month and 4.5 6 0.5 to Felsenfeld and Llach [12]: basal PTH, minimal PTH,
mg/day at six months. maximal PTH, and the basal/maximal PTH ratio when
PTH levels are expressed in absolute values; slope (calcu-
Biochemical follow-up lated from the more linear part of the curve), and set
Blood samples were collected immediately before sur- point of Ca (as iCa concentration corresponding to 50%
gery and at 15 days and 1-, 3-, and 6-months post-KT. The maximal PTH) when PTH levels are expressed as per-
following serum parameters were measured: creatinine, centages of maximal PTH.
iCa, phosphorus, and intact PTH. In addition, as previously described [13], we also evalu-
1-25(OH)2 vitamin D3 and osteocalcin [bone Gla pro- ated the slope and the set point derived from the limited
tein (BGP)] were measured before KT and at one-, calcium-mediated PTH-suppression curve, respectively,
three-, and six-months post-KT. Phosphorus and creati- defined as partial slope and EC50. For calculation of these
nine determinations were performed using a Technicon two parameters, the curves derived from the PTH-sup-
Autoanalyzer. iCa was determined with a Corning ana- pressibility test results were expressed as percentages of
lyzer. Intact PTH was measured using a two-site chemi- basal PTH for each patient, and the data were linearized
luminometric immunoassay for human PTH 1-84 (Magic by plotting the natural logarithm (Ln) of the percentage
Lite; Ciba Corning Diagnostics Corp., Medfield, MA, of basal PTH versus the iCa concentration at each time
USA). BGP was determined by radioimmunoassay (PR; point. Linear regression analysis generated the regres-
Cis Biointernational, Gif-sur-Yvette, France). Serum sion equation: Ln(% basal PTH) 5 a 1 b[iCa]. Partial
slope, defined as b, represents the sensitivity of the para-1,25(OH)2-vitamin D3 was assessed with a radioreceptor
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thyroid cell to the iCa increment. EC50, defined as the six months, with the mean level attaining the normal
range as early as the first month (Fig. 1D).iCa concentration at 50% of the maximal PTH suppres-
Serum BGP rapidly declined during the first month andsion, is thought to have the same meaning of the set
then gradually increased to threefold the upper limit ofpoint [13]: [(100% 1 ending PTH% suppression)/2].
the normal range, where it remained constant (Fig. 1E).
Statistical analysis
Ionized calcium and parathormone changes duringAll the results are expressed as means 6 sem. For
CaCl2 infusioncomparison of basal data between different time periods
As shown in Figure 2A, infusion of CaCl2 induced aor for comparison of PTH concentrations during dy-
progressive and significant increase of serum iCa levels.namic tests between one- and six-months post-KT, we
It should be noted that the mean iCa levels at the endused Wilcoxon’s matched-pairs signed-rank test. For
of the tests were not different at one and six monthscomparison of different basal data at the same time, we
(1.73 6 0.05 vs. 1.79 6 0.02 mmol/liter, P 5 NS). Thereused Spearman’s correlation test. The software used was
was also no difference between the two times concerningStata 4.0 (Stata Corp., College Station, TX, USA). Statis-
either the magnitude of the iCa increase (0.43 6 0.04 vs.tical significance was defined as P , 0.05.
0.46 6 0.02 mmol/liter, P 5 NS) or the rate of increase
assessed by the slope of the regression line of serum iCa
RESULTS against time (0.0023 vs. 0.0022 mmol/liter/min, P 5 NS).
These results enabled us to compare the mean PTHBaseline and post-kidney transplant evolution of
concentrations between one- and six-months post-KT atbone-metabolism parameters and renal function
each time point of the tests. At both times, serum PTHAll patients had a functioning renal graft, as assessed
levels decreased in a curvilinear manner (Fig. 2B). Theby the onset of diuresis and the decrease of serum creati-
comparison revealed that the mean PTH concentrationsnine, within the first postoperative days, except for one
were lower at six months than at one month at each timepatient, who presented transiently delayed graft function
point. This difference was always significant (P , 0.05),during the first week after KT. Renal function, assessed
except at 180 minutes, thus suggesting improvement ofby serum creatinine and isotopic clearance of 51CrEDTA,
parathyroid function between the two times.
remained stable in all patients throughout the entire
Concerning the kinetic parameters of the iCa/PTH
duration of the study. Mean serum creatinine was 124 6
curves (Table 2), a minimal PTH-secretion plateau de-
12 mmol/liter at one-month and 122 6 10 mmol/liter at fining minimal PTH could be obtained for all patients
six-months post-KT (P 5 NS), and the mean GFR was at one and six months. Between one and six months, the
48 6 5 ml/min at one-month and 57 6 8 ml/min at six mean minimal PTH decreased significantly from 25 6 6
months post-KT (P 5 NS). The evolution of the bone to 15 6 5 pg/ml (P 5 0.005). On the other hand, when
metabolism parameters during the study is shown in Fig- the curves were plotted as the percentage of basal PTH
ure 1. against iCa (Fig. 3), no change of either EC50 or the
Serum iCa (Fig. 1A), which was at the lower limit of partial slope was observed during this period.
the normal range before KT, increased significantly,
from 1.21 6 0.02 to 1.35 6 0.03 mmol/liter at the third Ionized calcium and parathormone changes during
month (P , 0.03) and then remained stable. Between Na2-EDTA infusion
three and six months, 64% (7/11) of the patients pre- Infusion of Na2-EDTA induced a progressive decline
sented hypercalcemia (iCa . 1.3 mmol/liter). During in serum iCa (Fig. 4A). The mean iCa levels at the end
that period, iCa was positively correlated with PTH lev- of the tests were not statistically different at one and six
els (at three months, P , 0.02; at six months, P , 0.03). months (1.03 6 0.03 vs. 1.08 6 0.03 mmol/liter, P 5 NS).
Serum phosphorus (Fig. 1B) dramatically decreased Concerning iCa changes, there were no differences in
during the first month from 1.68 6 0.1 to 0.76 6 0.1 mmol/ the magnitude of the decrease (0.27 6 0.01 vs. 0.25 6
liter (P , 0.003), increased slightly after one month to 0.02 mmol/liter, P 5 NS) or in the slope of the regression
reach the normal range, and then remained unchanged line of serum iCa against time (20.0014 mmol/liter/min).
during follow-up. Seven of the 11 patients developed These results enabled PTH concentrations to be com-
transient hypophosphoremia during the study. pared between one- and six-months post-KT at the dif-
At the time of KT, the mean basal serum PTH concen- ferent time points. During the tests, serum PTH levels
tration was 195 6 54 pg/ml, and this decreased rapidly progressively increased (Fig. 4B). A comparison re-
during the first 15 days after KT (P , 0.05). Between vealed that PTH levels were significantly lower at six
one and six months, a significant decrease until 70 6 12 months than at one month at each time point, suggesting
pg/ml (P , 0.02) was also observed (Fig. 1C). a marked improvement of parathyroid function between
the two times post-KT.Serum calcitriol progressively increased over the first
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Table 2. Evolution of the kinetic parameters of the iCa/PTH curves
between 1 and 6 months after KT (N 5 11)
Parameter 1 month 6 months P
Minimal PTH pg /ml 2566 15 65 0.005
EC50 mmol /liter 1.3760.03 1.38 60.01 NS
Partial slope 26.661.2 29.462.4 NS
Maximal PTHa pg /ml 340691 220 630 0.03
Slopea %/mmol·l21 2369660 2365636 NS
Set pointa mmol /liter 1.2560.03 1.27 60.03 NS
Basal/max PTHa % 3363 27 62 NS
Results are expressed as means 6 sem.
a N 5 7
Fig. 3. Ionized calcium (iCa)/parathormone (PTH) curves based on
the hypercalcemia tests of the 11 patients with PTH levels expressed
as the percentage of basal PTH (means 6 SEM) at one (d) and six
months (h) after transplantation. EC50 and partial slope were not sig-
nificantly different for the two times.Fig. 2. (A) Serum intact calcium (iCa) concentrations during a three-
hour infusion of calcium (CaCl2) one month (d) and six months (h)
after kidney transplantation (KT). Values are expressed as means 6
sem for the 11 patients. The magnitude, rate of iCa increase, and the
end iCa levels were comparable at the two times. (B) Parathormone two test times showed lower absolute PTH levels six
(PTH) levels during a three-hour infusion of calcium at one month (d) months after KT when the entire range of iCa concentra-and six months (h) after KT. Values are expressed as the means 6
tions was considered, with a significant difference on thesem of the 11 patients. *P , 0.05; **P , 0.01 indicate differences
between PTH values at one- and six-months post-KT at the designated iCa intervals ranging from 0.95 to 1.05 and 1.41 to 1.75
time points. mmol/liter (Fig. 5A). However, when the curves were
plotted with PTH levels expressed as percentages of max-
imal PTH, neither the set point of calcium nor the slope
of the entire curve varied significantly (Table 2 and Fig.Maximal PTH was defined as the highest PTH-secre-
5B) between one- and six-months post-KT. The basal/tion plateau reached by the patients during Na2-EDTA maximal PTH ratio did not vary significantly during thisinfusion. In this respect, we excluded four patients for
period, indicating no change of the basal operationalwhom such a plateau could not be obtained at the two
status of the glands between the two periods.
tests: Two patients did not reach a maximal secretion
plateau at one month. Another did not attain it at six
DISCUSSIONmonths, and the last one had no maximal secretion pla-
teau at one and six months. In the seven patients for This study was designed to determine the changes in
whom the comparison was possible, the mean maximal parathyroid function after KT. Using both static and
PTH concentration decreased from 340 6 91 at one month dynamic tests in patients with mild or moderate biochem-
to 220 6 30 pg/ml at six months (P 5 0.03; Table 2). ical HPT II, we observed between one- and six-months
Plotting the results of both hypocalcemia and hypercalce- post-KT significantly decreased mean PTH concentra-
mia tests together for these seven patients generated the tions over a wide range of iCa levels, indicating improved
well-known sigmoidal curve of the iCa/PTH relationship. parathyroid function. The evolution of the kinetic pa-
rameters of the iCa/PTH relationship curve suggests thatA comparison of the composite iCa/PTH curves for the
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this improvement is mainly due to a reduction of the
parathyroid functional mass. One month after KT, the
mean maximal PTH and minimal PTH levels, both indi-
cators of functional mass [12], were approximately three-
fold higher than those reported in normal subjects [9].
Five months later, a significant decrease of these parame-
ters, by more than 35%, was observed. To the best of
our knowledge, such a sequential study post-KT has
never been conducted in humans. A previous compari-
son of the mean iCa/PTH curve of transplant recipients
with that of a normal control group [7, 14] led the authors
to conclude that the very high PTH levels, which were
measured at all iCa levels in the transplant-recipients
group, likely reflected increased gland mass rather than
altered sensitivity of the parathyroid cell, because there
was no difference between the slopes of the curves for
the two groups. More recently, using a model of experi-
mental HPT II in 5/6 nephrectomized rats, parathyroid
function was studied before and after isogenic KT [15].
As in our patients, HPT II was rapidly reversed with
normalization of both maximal and minimal PTH values
shortly after transplantation, but the slope and set point
were not evaluated in this study [15]. In our current
study, we did not observe any significant change in these
parameters assessed by the entire curve (set point, slope)
or the limited PTH-suppression portion of the curve
(EC50, partial slope). These data suggest that the correc-
tion in the regulation of PTH release by iCa does not
account for the lowering of PTH secretion after KT.
However, the real physiopathological meaning of the set Fig. 4. (A) Serum ionized calcium (iCa) concentrations during a three-
hour infusion of Na2-EDTA at one (d) and six months (h) after kidneypoint must be interpreted with caution, as some authors
transplantation (KT). Values are expressed as means 6 sem of the 11consider that it might not necessarily reflect a specific
patients. The magnitude, rate of iCa decrement, and the end iCa level
intrinsic property of the parathyroid gland in vivo and were comparable at the two times. (B) PTH levels during a three-hour
infusion of Na2-EDTA at one month (d) and six months (h) after KT.could be directly modified by sustained changes in the
Values are expressed as means 6 sem of the 11 patients. *P , 0.03 andexisting serum iCa [16, 17].
**P , 0.01 denote differences between PTH values at one and six
It has long been known that parathyroid enlargement months post-KT at the designated time points.
is a major determinant of PTH hypersecretion [18], thus
explaining the success of surgical parathyroid mass re-
duction. A few studies [13, 14] have established a rela-
phy [22], or hyperplasia [23]. The significant rise of iCationship between functional mass parameters and the
observed in our patients during the first three monthsparathyroid size evaluated by ultrasonography [13] or
led to a reduction of basal PTH, and furthermore, hyper-measured at the time of parathyroidectomy in transplant
calcemia observed after the third month (mean iCapatients [14]. Therefore, our findings could be compati-
level . 1.30 mmol/liter) likely contributed to improveble with a reduction of the gland’s size due to regression
the parathyroid function. Moreover, these changes inof parathyroid cell hypertrophy or hyperplasia, although
iCa could be the consequence of the progressive recoveryin this study, the anatomical parathyroid mass was not
of the normal calcemic activity of PTH. Many factorsevaluated. However, experimental studies tend to dem-
involved in the resistance to this PTH activity duringonstrate that cellular hypertrophy is much more easily
uremia, including hyperphosphatemia, low calcitriolreversible than hyperplasia after removal of stimuli (ab-
level, and uremia itself, tended to normalize after KT instract; Chin et al, J Bone Miner Res 11(Suppl 1):S121,
our patients. Subsequently, after the third-month post-1996) [19–21].
KT, we, like other researchers, found a positive correla-The improvement of the parathyroid function may be
tion between PTH and iCa [6, 24].due to changes in calcemia, phosphoremia, and calcitriol
The second factor potentially able to explain the im-levels observed after KT. Prolonged hypocalcemia has
been implicated in parathyroid gland growth, hypertro- proved parathyroid function is the recovery of normal
Bonarek et al: Post-transplant parathyroid function648
phorus in our patients who thereafter were all normo-
phosphoremic or hypophosphoremic. Hyperphosphore-
mia is one of the major causes of HPT II [30, 31]. Indeed,
a direct effect of phosphorus on PTH secretion has been
established [11, 32–34], and it has been shown that phos-
phorus restriction could prevent parathyroid gland
growth [34]. However, some authors failed to demon-
strate a change in the size of the parathyroid glands in
uremic rats with severe hyperparathyroidism fed with a
low-phosphorus diet (abstract; Takahashi et al, J Am
Soc Nephrol 8:580A, 1997).
However, in spite of all of these beneficial metabolic
and endocrine changes, the normalization of parathyroid
function is not complete six months after KT. The main
features of this incomplete correction are the persistently
high basal PTH, iCa, and BGP concentrations. In partic-
ular, BGP, after an initial transient decline because of
the high corticosteroid dose [2, 35], remains more than
threefold above the normal range at six-months post-
KT, suggesting the persistence of abnormally high bone
turnover. For some authors the persistent HPT II after
KT does not show any spontaneous tendency to improve
[3, 4]. A first explanation for this abnormality is the
persistence of parathyroid hyperplasia, linked to its slow
regression, because parathyroid tissue undergoes low cell
turnover [19, 36].
The occurrence before KT of nodular parathyroid
growths, known to be insensitive to calcitriol’s inhibitory
action [37] and unable to regress [38], seems unlikely in
our patients.
On the other hand, although renal function can gener-
Fig. 5. Composite iCa/PTH curves from seven patients for whom a ally be considered optimal in our transplant recipients,
plateau of maximal secretion of parathormone (PTH) could be obtained with a mean GFR of about 50 ml/min, this rate is certainlyone and six months post-KT. (A) PTH expressed as means 6 sem of
insufficient to suppress all of the PTH stimulatory signalsthe absolute values at one-month (d) and six months (h) after KT.
*P , 0.05 denotes differences between PTH values at one and six and insure the normalization of the parathyroid function,
months post-KT at the designated iCa level. (B) PTH, expressed as the which probably is one of the main factors explaining thispercentage of maximal PTH at one (d) and six months (h) after KT,
persistent HPT.showed no change of either the set point or the slope of the curves at
the two times. In conclusion, KT rapidly induces a partial reversibility
of HPT II in patients with mild or moderate biochemical
HPT II. Through a sequential determination of the iCa/
PTH relationship curve, we found that the improved
circulating calcitriol levels observed during the first parathyroid function observed between the first month
months after KT. The direct suppressive effect of and the sixth month after KT seemed mainly to be caused
calcitriol on the parathyroid gland has been well estab- by a reduction of the parathyroid functional mass. Maybe
lished, not only on PTH synthesis, but also on cellular such an evolution in these patients was possible because
proliferation [12, 23, 25, 26]. It should be noted that they did not present with severe HPT II, and thus, there
a regression of parathyroid enlargement, assessed by may have been no severe histological parathyroid changes
ultrasonography, and improvement of parathyroid func- such as nodular growth. It will be interesting to study
tional mass parameters by more than 30% have been the evolution of the parathyroid function after KT in
reported after calcitriol therapy in hemodialysis patients patients with more severe HPT II, and determine the
[27, 28]. Furthermore, the elimination of uremic toxins extent of the recovery and the time necessary under
following KT probably improves the calcitriol–receptor optimal transplantation conditions.
interaction with its target gene [29].
The third major factor is the normalization of serum ACKNOWLEDGMENTS
phosphorus. Like others [1, 2], during the first month The authors gratefully thank Dr. Dany Montaudon for her expert
technical assistance, the nursing staff, and Dr. Julie De´chanet and Dr.post-KT we observed a rapid decrease of serum phos-
Bonarek et al: Post-transplant parathyroid function 649
Vale´rie De Pre´cigout for precious advice in the preparation of the 18. Stanbury SW, Lumb GA: Parathyroid function in chronic renal
failure. Q J Med 35:1–23, 1966manuscript.
19. Parfitt AM: The hyperparathyroidism of chronic renal failure: A
disorder of growth. Kidney Int 52:3–9, 1997Reprint requests to Dr. Pierre Merville, Service de Ne´phrologie et
Transplantation Re´nale, Hoˆpital Pellegrin, place Ame´lie-Raba-Le´on, 20. Wang Q, Palniktar S, Parfitt AM: Parathyroid cell proliferation
in the rat: Effect of age, and of phosphate administration and33076 Bordeaux Cedex, France.
E-mail: Pierre.Merville@chu-aquitaine.Fr recovery. Endocrinology 137:4558–4562, 1996
21. Capen CC, Cole CR, Hibbs JW, Wagner AR: Bioassay and quanti-
tative morphology analysis of the parathyroid glands, and serum
REFERENCES and urine changes of cows fed high levels of vitamin D. Am J Vet
Res 27:1177–1186, 19661. Alsina J, Gonzalez MT, Bonnin R, Ricart Y, Castelao AM,
22. Wernerson A, Windholm S, Svenson O, Reinholt F: ParathyroidGonzalez C, Grino JM: Long-term evolution of renal osteodystro-
cell number and size in hypocalcemic young rats. APMIS 99:1096–phy after renal transplantation. Transplant Proc 21:2151–2158, 1989
1102, 19912. Saha HH, Salmela KT, Ahonen PJ, Pietila¨ KO, Mo¨rsky PJ,
23. Naveh-Many T, Silver J: Regulation of parathyroid hormone geneMustonen JT, Lalla ML, Pasternack AI: Sequential changes in
expression by hypocalcemia, hypercalcemia, and vitamin D in thevitamin D and calcium metabolism after successful renal trans-
rat. J Clin Invest 86:1313–1319, 1990plantation. Scand J Urol Nephrol 28:21–27, 1994
24. Koyama Y, Miyazato T, Hatano T, Ogawa Y: Can successful3. Parfitt AM: Hypercalcemic hyperparathyroidism following renal
renal transplantation resolve secondary hyperparathyroidism?transplantation: Differential diagnosis, management, and implica-
Transplant Proc 28:1644–1645, 1996tions for cell population control in the parathyroid gland. Miner
25. Russel J, Lettieri D, Sherwood LM: Suppression by 1,25(OH)2D3Electrolyte Metab 8:92–112, 1982
of transcription of the pre-proparathyroid hormone gene. Endocri-4. Dumoulin G, Hory B, Nguyen NU, Bresson C, Fournier V,
nology 119:2864–2866, 1986Bouhaddi M, Chalopin JM, Saint-Hillier Y, Regnard J: No
26. Szabo A, Merke J, Beier E, Mall G, Ritz E: 1,25(OH)2 vitamintrend toward a spontaneous improvement of hyperparathyroidism
D3 inhibits parathyroid cell proliferation in experimental uremia.and high bone turnover in normocalcemic long-term renal trans-
Kidney Int 35:1049–1053, 1989plant recipients. Am J Kidney Dis 29:746–753, 1997
27. Fukagawa M, Okazaki R, Takano K, Kaname S-Y, Ogata E,5. Pietschmann P, Vychytil A, Woloszczuk Kovarik J: Bone me-
Kitaoka M, Harada S-I, Sekine N, Matsumoto T, Kurokawa K:tabolism in patients with functioning kidney graft: Increased serum
Regression of parathyroid hyperplasia by calcitriol-pulse therapylevels of osteocalcin and parathyroid hormone despite normaliza-
in patients on long-term dialysis. N Engl J Med 323:421–422, 1990tion of kidney function. Nephron 59:533–536, 1991
28. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibi-6. Vezzoli G, Elli A, Palazzi P, Bertoni T, Scabini M, Quarto
tory effect of calcitriol on parathyroid function (sigmoidal curve)di Palo F, Bianchi G: High plasma ionized calcium with normal
in dialysis. Kidney Int 36:1093–1098, 1989PTH and total calcium levels in normal-function kidney transplant
29. Hsu CH, Patel SR: Altered vitamin D metabolism and receptorrecipients. Nephron 42:290–294, 1986
interaction with the target genes in renal failure: Calcitriol receptor7. McCarron DA, Bennett WM, Muther RS, Barry JM, Krutzik
interaction with its target gene in renal failure. Curr Opin NephrolS: Posttransplantation hyperparathyroidism: Demonstration of re-
Hypertens 4:302–306, 1995tained control of parathyroid function by plasma ionized calcium.
30. Slatopolsky E, Caglar S, Pennel JP, Taggart D, CanterburyAm J Clin Nutr 33:1536–1540, 1980
JM, Reiss E, Bricker NS: On the pathogenesis of hyperparathy-8. Mitlak BH, Alpert M, Lo C, Delmonico F, Neer RM: Parathyroid
roidism in chronic renal insufficiency in the dog. J Clin Investfunction in normocalcemic renal transplant recipients: Evaluation
50:492–499, 1971by calcium infusion. J Clin Endocrinol Metab 72:350–355, 1991
31. Llach F: Secondary hyperparathyroism in renal failure: The trade-9. Brent GA, Leboff MS, Seely EW, Conlin PR, Brown EM: Rela-
off hypothesis revisited. Am J Kidney Dis 25:663–679, 1995tionship between the concentration and rate of change of calcium
32. Lopez-Hilker S, Dusso AS, Rapp NS, Martin KJ, Slatopolskyand serum intact parathyroid hormone levels in normal humans.
E: Phosphorus restriction reverses hyperparathyroidism in uremiaJ Clin Endocrinol Metab 67:944–950, 1988 independent of changes in calcium and calcitriol. Am J Physiol10. Garnett EJ, Parsons V, Veall N: Measurement of GFR in man 259:F432–F437, 1990using a 51Cr EDTA complex. Lancet 1:818–819, 1967 33. Aparicio M, Combe C, Lafage MH, Precigout VD, Potaux L,
11. Combe C, Aparicio M: Phosphorus and protein restriction and Bouchet JL: In advanced renal failure, dietary phosphorus restric-
parathyroid function in chronic renal failure. Kidney Int 46:1381– tion reverses hyperparathyroidism independent of changes in the
1386, 1994 levels of calcitriol. Nephron 63:122–123, 1993
12. Felsenfeld AJ, Llach F: Parathyroid gland function in chronic 34. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso
renal failure. Kidney Int 43:771–789, 1993 AS, McDonald PN, Brown AJ: Phosphorus restriction prevents
13. Indridason OS, Heath H III, Khosla S, Yohay DA, Quarles parathyroid gland growth: High phosphorus directly stimulates
LD: Non-suppressible parathyroid hormone secretion is related to PTH secretion in vitro. J Clin Invest 97:2534–2540, 1996
gland size in uremic secondary hyperparathyroidism. Kidney Int 35. Lukert BT, Higgins JC, Stoskopf MM: Serum osteocalcin is in-
50:1663–1671, 1996 creased in patients with hyperparathyroidism and decreased in
14. McCarron DA, Muther RS, Lenfesty B, Bennett WM: Parathy- patients receiving glucocorticoids. J Clin Endocrinol Metab
roid function in persistent hyperparathyroidism: Relationship to 62:1056–1058, 1986
gland size. Kidney Int 22:662–670, 1982 36. Wang Q, Palnitkar S, Parfitt AM: The basal rate of cell prolifera-
15. Lewin E, Wang W, Olgaard K: Reversibility of experimental tion in normal human parathyroid tissue: Implications for the
secondary hyperparathyroidism. Kidney Int 52:1232–1241, 1997 pathogenesis of hyperparathyroidism. Clin Endocrinol 46:343–349,
16. Felsenfeld AJ, Rodriguez M: The set point of calcium: Another 1997
view. Nephrol Dial Transplant 11:1722–1725, 1996 37. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa
17. Borrego MJ, Felsenfeld AJ, Martin-Malo A, Almaden Y, Con- S, Seino Y: Decreased 1,25-dihydroxyvitamin D3 receptor density
cepcion MT, Alijama P, Rodriguez M: Evidence for adaptation is associated with a more severe form of parathyroid hyperplasia
of the entire PTH-calcium curve to sustained changes in the serum in chronic uremic patients. J Clin Invest 92:1436–1442, 1993
calcium in haemodialysis patients. Nephrol Dial Transplant 12:505– 38. Dru¨eke TB: The pathogenesis of parathyroid gland hyperplasia
513, 1997 in chronic renal failure. Kidney Int 48:259–272, 1995
